Blood draw
Diagnostic TestEvaluation of plasma inflammatory markers including cytokines and micro-RNA.
NCT Number: NCT04259125
The purpose of this study evaluate the relationship between inflammation and epilepsy in neonates with seizures after birth.
Looking for future studies?
Notify Me1 day–4 day
All sexes
Observational
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Seizures are a common symptom of neurologic dysfunction in the neonatal period, affecting more than 16,000 newborns in the United States per year. Over 25% of neonates with acute symptomatic seizures develop post- neonatal epilepsy (PNE), which is often resistant to medical therapies. There is a critical need to identify those patients most at risk for PNE and understand the mechanisms by which early seizures increase the propensity for recurrent seizures, in hopes of identifying novel therapeutic targets in this population. There is increasing evidence for the role of neuro-inflammation in the development of epilepsy. Levels of cytokines and micro-RNA (miRNA) may serve as markers of disease severity and have been implicated in epileptogenesis in animal models. The purpose of this study is to evaluate plasma cytokine and miRNA levels after neonatal-onset acute symptomatic seizures and determine their association with acute seizure severity and PNE.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
For participants in the acute symptomatic seizure group:
Inclusion criteria
Exclusion criteria
For participants in the control group:
Inclusion criteria
Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
Regarding epilepsy and development.
Time frame: At study entry
Investigators will evaluate the seizure burden from the initial diagnostic electroencephalogram (EEG) after birth by determining the average number of seizures per hour.
Time frame: 24 months of age
The investigators will determine the proportion of participants who develop clinical and or electrographic seizures.
Time frame: 12 months of age
The investigators will determine the proportion of participants who develop clinical and or electrographic seizures.
Time frame: 12 months of age
The investigators will administer an investigator-developed questionnaire designed to define the frequency of seizures (monthly, weekly, daily, or greater than daily).
Time frame: 24 months of age
The investigators will administer an investigator-developed questionnaire designed to define the frequency of seizures (monthly, weekly, daily, or greater than daily).
Time frame: Assessment takes up to 15 minutes and will be conducted at 12 months of age
The Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) will be assessed at 12 months of age. The score ranges from 50 to 200 with higher scores associated with normal development.
Time frame: Assessment takes up to 15 minutes and will be conducted at 24 months of age
The Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) will be assessed at 24 months of age. The score ranges from 50 to 200 with higher scores associated with normal development.
University of California, San Francisco
Other
Neonatal Seizure Registry: The Role of Inflammation After Neonatal Seizures and Later Development of Epilepsy
Acronym: NSR-RISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04337697
Brain Damage, Chronic, Brain Diseases
San Francisco, California, United States
View Trial DetailsNCT05361070
Brain Diseases, Brain Ischemia
San Francisco, California, United States
View Trial DetailsNCT06211192
Neonatal Seizure, Nervous System Diseases
Balıkesir, Altieylul, Turkey (Türkiye)
View Trial DetailsNCT01747863
Brain Diseases, Brain Injuries
Detroit, Michigan, United States
View Trial Details